A researcher from the Université Laval, who is working on a drug against alzheimer’s will be able to count on the support of a venture capital fund in quebec which will invest $ 1.2 million in its work.
AmorChem will fund the work of three researchers in quebec’s Laval and McGill universities for a total of$ 3.6 Million. In Quebec, it is the work of the researcher Serge Rivest, specialized in neuro-immunology, which have attracted the venture capital fund life science. Eventually, the partnership could lead to the commercialization of a drug against alzheimer’s.
“I’m working on an immunotherapy for alzheimer’s disease for 20 years, and we have identified molecules as very promising, which could help prevent the onset of symptoms in people at risk,” says Dr. Rivest.
Medicine in the next three years ?
The investment of$ 1.2 Million made by AmorChem will allow the researcher to accelerate its work.
“We have developed a model which allows to incubate the technologies by paying directly to the university and where there are valid results quickly,” says the co-founder of AmorChem, Elizabeth Douville.
Specifically, Dr. Rivest and his team, such a partnership means that they will be set for the future in 18 months.
“We now have the means to know if you have something that works extremely well, as is commonly believed, at the end of 18 months. And then, the goal is to develop the finished product and to commercialize it by founding a company. It can go quite fast, in a horizon of two or three years from there “, explains the researcher, stating that he and his team would then be “the first in the world” to accomplish such a tour de force.
Continue, despite the COVID-19
AmorChem was important to make these investments despite the global crisis of the COVID-19 and the delays that it causes in the search.
“Some have been able to put on the brakes to protect their investments, but the COVID-19 has highlighted the fact that despite all that is happening, people continue to get sick and research is paramount. This is what convinced us to move forward, ” Ms. Douville, who sees the investment as a way to participate in the recovery of the economy.
“The pandemic has taken a lot of delay in closing the labs, so it is doubly important to redouble our efforts to help people who suffer from diseases such as alzheimer’s disease,” notes Dr. Rivest, who has made the fight of his life.